Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials

18 Jul, 2021

Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials
Photo by Michael Longmire on Unsplash

– Wugen, Inc. completed an oversubscribed $172m Series B financing led by Abingworth and Tybourne Capital Management, and joined by new investors Fidelity Management and Research Company, Intermediate Capital Group, Sands Capital, Aisling Capital Management, Alexandria Venture Investments, Velosity Capital and Falcon Edge Capital.
– Existing investors, including RiverVest Venture Partners, LYZZ Capital, and Lightchain Capital, also participated.
– In connection with the financing, Bali Muralidhar, M.D., Ph.D., Managing Partner at Abingworth, Bosun Hau, Managing Director at Tybourne Capital Management, and Peter Kiener, Ph.D., Venture Partner at ICG, will join Wugen’s Board of Directors.

Biotechnology North America Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: